LAUSR

Androgenetic alopecia (AGA) and telogen effluvium (TE) are common causes of hair loss, with limited options for treatment. The aim of this study was to determine the efficacy and safety of a new formulation kit (Pielus Anti‐hair loss lotion and shampoo) containing anti‐inflammatory and antioxidant agents in patients with TE and/or AGA. This was a prospective, single‐arm, open‐label study with 35 women and 10 men, median age of 44 years, with clinical diagnosis of TE and/or AGA. They used the combination of shampoo and lotion daily for 90 days. There was nonoccurrence of adverse events. Phototricogram showed increase in the average number of anagen hairs at T90 (P < .001). Scalp microphotography showed increase in total follicular units, total of hairs, and median hair per follicle unit at T90. There was an increase in diameter (P = .003) and in median maximum load and resistance to traction in T90 (P = .040). Combing and washing test demonstrated a decrease in the number of shed hairs before washing (P = .005), after washing (P = .01) and in total (P < .001). The use of shampoo+ lotion daily was safe and effective to attenuate hair loss in men and women with TE and/or AGA.